Iterum Therapeutics PLC
NASDAQ:ITRM

Watchlist Manager
Iterum Therapeutics PLC Logo
Iterum Therapeutics PLC
NASDAQ:ITRM
Watchlist
Price: 1.26 USD -3.08% Market Closed
Market Cap: 43.6m USD

During the last 3 months Iterum Therapeutics PLC insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 15% over this period (open performance analysis).

The last transaction was made on Dec 22, 2023 by Dunne Michael W. (Principal Financial Officer) , who bought 35k USD worth of ITRM shares.

Last Transactions:
Dunne Michael W.
Principal Financial Officer
$+35k
Dunne Michael W.
Principal Financial Officer
$+18.4k
Dunne Michael W.
Principal Financial Officer
$+40.7k
Fishman Corey N.
Chief Financial Officer
$+15.9k
Puttagunta Sailaja
Chief Financial Officer
$-4.4k
Ahrens Brenton Karl
Chief Financial Officer
$-28.5k
Ahrens Brenton Karl
Chief Financial Officer
$-32.1k
Ahrens Brenton Karl
Chief Financial Officer
$-7.5k
Dunne Michael W.
Principal Financial Officer
$+22.2k
Matthews Judith M.
Chief Financial Officer
$-1.2k
Denner Alexander J
Chief Executive Officer
$-1.7m
Matthews Judith M.
Chief Financial Officer
$-3.9k
Fishman Corey N.
Chief Financial Officer
$-9.9k
Dunne Michael W.
Principal Financial Officer
$-3.8k
Matthews Judith M.
Chief Financial Officer
$-6.1k
Sofinnova Venture Partners Ix, L.p.
Lead Investor
$-11.3k
Kelly David George
Chief Executive Officer
$+4.2k
Dunne Michael W.
Principal Financial Officer
$+330
Dunne Michael W.
Principal Financial Officer
$+330
Edick Paul R
Chief Financial Officer
$+344.4
Fishman Corey N.
Chief Financial Officer
$+1.2k
Chin Mark
Chief Financial Officer
$+292.6k
Matthews Judith M.
Chief Financial Officer
$+3.5k
Canaan Partners X Llc
Director
$+439.1k
Fishman Corey N.
Chief Financial Officer
$+2.6k
Dunne Michael W.
Principal Financial Officer
$+1.7k
Malik Shahzad
Chief Financial Officer
$+7.1k
Heron Patrick J
Chief Executive Officer
$+307.6k
Ratcliffe Liam
Non-Executive Chairman
$+241k
Ahrens Brenton Karl
Chief Financial Officer
$+439.1k
Hunt Ronald
Director
$+241k
Healy James
Chief Financial Officer
$+433.3k
View All Transactions

During the last 3 months Iterum Therapeutics PLC insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 15% over this period (open performance analysis).

The last transaction was made on Dec 22, 2023 by Dunne Michael W. (Principal Financial Officer) , who bought 35k USD worth of ITRM shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Iterum Therapeutics PLC
Insider Trading Chart

Iterum Therapeutics PLC
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Iterum Therapeutics PLC
Last Insider Transactions

Global
Insiders Monitor

Iterum Therapeutics PLC
Glance View

Market Cap
39.7m USD
Industry
Pharmaceuticals

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.

ITRM Intrinsic Value
1.34 USD
Undervaluation 6%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top